The canonical wnt signaling pathway has also been studied [16], Indeed, studies on the canonical wnt signaling sclerostin led to the development of a therapeutic agent directed against the inhibitor sclerostin for the treatment of osteoporosis that was recently approved for use in patients in the US [17]. The gene discussed is SOST; the disease is osteoporosis.